Companies ›Healthcare ›CNTX

CNTX — Nasdaq Pharmaceuticals

Context Therapeutics Inc.

$0,60

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

57,1M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

-16,6 %

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$0,61

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapies, primarily through asset acquisitions and internal research, with no current product revenue.

Business. Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapies, primarily through asset acquisitions and internal research, with no current product revenue.

Classification98 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY10 analysts

10 buy0 hold0 sell

Avg 12m price target5,38

Analyst recommendations

10 analysts · consensus Buy

Buy10

Hold0

Sell0

12-month price target

5,38

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

10 analysts · indicative

Ownership→

Franklin Advisers, Inc.

largest disclosed fund holder

Profitability→

-16,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning CNTX.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,7 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Energy+0,6 %+3,3 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Information Technology+0,2 %+7,9 %−0,4 %

Financials−0,3 %−3,0 %−1,0 %

Consumer Staples−0,7 %+2,5 %−1,3 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,8 %−1,6 %−2,4 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to CNTX. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-01 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapies, primarily through asset acquisitions and internal research, with no current product revenue.

Classification98 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

AI synthesis

GENERATED

Context Therapeutics maintains a strong liquidity position with $54.5 million in cash and equivalents against $6.7 million in total liabilities, resulting in a current ratio of 8.96 and zero debt-to-equity. The company holds a market capitalization of $57.1 million, trading at a price-to-book ratio of 1.09. Despite the robust balance sheet, the firm generated negative operating cash flow of $11.4 million in Q1 2026, driven by a net loss of $8.7 million and significant increases in prepaid expenses and accrued liabilities. Capital expenditures remain minimal at $37,258, indicating that cash burn is primarily attributable to operational and research costs rather than infrastructure investment.

Profitability metrics reflect the company's pre-revenue status, with a return on equity of -16.6% and a return on assets of -14.8%. The company has incurred losses since inception, accumulating a deficit of $139.6 million as of March 31, 2026. There is no revenue to support margin analysis, and the negative EV/EBITDA of -0.27 is not indicative of operational efficiency but rather the absence of earnings. The financial profile is typical of early-stage biotech firms where value is derived from intellectual property and clinical potential rather than current earnings power.

Key takeaways

Strong liquidity with $54.5M in cash and no debt, but accelerating cash burn of $11.4M in Q1 2026.
High dilution risk due to reliance on equity financing and existing option/warrant overhang.
No revenue; value derived from CT-95 asset acquisition and clinical pipeline potential.
Analyst consensus is strongly bullish with a mean price target of $5.38, implying ~800% upside.
Accumulated deficit of $139.6M underscores the long path to profitability.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-31

Q4 2025 · Quarter highlights

Open report →

Operating income -$9.3M.

Revenue—

Operating income-$9.3M

Net income-$8.7M

Free cash flow-$11.5M

EPS—

Operating cash flow-$11.4M

Financials

Income statement

Revenue—

Gross profit—

Operating income-$9.3M

Net income-$8.7M

Balance sheet

Total assets$58.9M

Total liabilities$6.7M

Total equity$52.2M

Cash & equivalents$54.5M

Long-term debt—

Cash flow

Operating cash flow-$11.4M

CapEx$37.3k

Free cash flow-$11.5M

SBC$409.2k

Highlights

▍Operating income -$9.3M

Valuation FY

Market price

$0,60

Market cap

$57.1M

Enterprise valueⓘ

$2.5M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

1.1x

P / Tangible bookⓘ

1.1x

Tangible book

$52.2M

Net cashⓘ

$54.5M

Current ratioⓘ

9.0

Debt / equityⓘ

—

ROAⓘ

-14.8%

ROEⓘ

-16.6%

Cash conversionⓘ

132.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

3.6%

Revenue by segment

Business relationships

Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures

Suppliers1

LONZA GROUP AGLON.NLBSupplier95%Source ↗

Supply chain

Vendors → CNTX ↔ Partners → Customers · click any node to drill

1 mention in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution10 analysts

Strong buy2

Buy8

Hold0

Sell0

Strong sell0

12-month price target$5,38 · Median $5,00

Low $4,00High $7,00

Operating income · consensus-41,1M USD

EPS surprise

+3,1 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$4,00

Mean$5,38

Median$5,00

High$7,00

Spot$0,60

+796.7 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskHigh

Liquidity riskLow

Filing-based flags

Diluted share count is moderately above the basic share count.
Source documents mention dilution or offering risk.

Benchmarks vs cohort

ROE-16,6 %Bottom quartile

D/E0,00Above P75

Cash Conv1,32Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 1 920 000 sh10 grants10 insiders

Pasternak AndyDirector · Stock Option (right to buy) → Common StockAcquired 45 000 @ $0,58grant · 2026-06-24
Kantoff Philip W.Director · Stock Option (right to buy) → Common StockAcquired 45 000 @ $0,58grant · 2026-06-24
Walker Luke NathanielDirector · Stock Option (right to buy) → Common StockAcquired 45 000 @ $0,58grant · 2026-06-24
Smith Karen L.Director · Stock Option (right to buy) → Common StockAcquired 45 000 @ $0,58grant · 2026-06-24
West LindaDirector · Stock Option (right to buy) → Common StockAcquired 45 000 @ $0,58grant · 2026-06-24
Stacey Jennifer EvansDirector · Stock Option (right to buy) → Common StockAcquired 45 000 @ $0,58grant · 2026-06-24
Minai-Azary Jennifer LynnChief Financial Officer · Stock Option (right to buy) → Common StockAcquired 275 000 @ $2,32grant · 2026-02-19
Lehr Martin A.Director, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 815 000 @ $2,32grant · 2026-02-19
Levit Alex C.Chief Legal Officer, Corp. Sec · Stock Option (right to buy) → Common StockAcquired 270 000 @ $2,32grant · 2026-02-19
Chagin Karen DeborahChief Medical Officer · Stock Option (right to buy) → Common StockAcquired 290 000 @ $2,32grant · 2026-02-19

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Cash Conversion Ratio
operating_cash_flow / net_income
Market Price
input from market-data provider (delayed close or quote-shim mid)
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Market Cap
market_price * shares_outstanding_diluted
Debt To Equity
(short_term_debt + long_term_debt) / total_equity

Source documents

Context Therapeutics Inc. company facts · 2026-08-01
Context Therapeutics Inc. 10-Q 2026-05-06 · 2026-08-01
Context Therapeutics Inc. 10-K 2026-03-23 · 2026-08-01
Context Therapeutics Inc. 10-Q 2025-11-05 · 2026-08-01
Context Therapeutics Inc. 10-Q 2025-08-06 · 2026-08-01
8-K (sec_8k_material) on CNTX · 2026-08-01
Context Therapeutics Inc Market data — analyst estimates · 2026-08-01
Context Therapeutics Inc. HA canonical relationships · 2026-08-01

Ownership & reference

Top holders

Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$10M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$2M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$6M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$2M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$1M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

Insider activity

— missing data

Short positioning

6.6Mshares short+106.5% vs prior

1.81days to cover

61.7%short of daily vol

30.7Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

CNTXCanonical

Nasdaq · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskHigh

Liquidity riskLow

Diluted share count is moderately above the basic share count.

Source documents mention dilution or offering risk.

Relationship graph

This companySectorSuppliers

Evidence & claims

From filings & derived data

Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -81.3%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -32.7%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -36.5%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 180.4%Derived (calculated)
Return on equity (FY 2025-12-31): -59.7%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 0.13xDerived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -30.2%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -30.1%Derived (calculated)
Current ratio (FY 2025-12-31): 8.52xDerived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 17.4%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 364.0%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 17.4%Derived (calculated)
Return on assets (FY 2025-12-31): -52.7%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -35.2%Derived (calculated)
Current liabilities (annual): USD 8.02MSEC XBRL filing
Operating cash flow (annual): USD -26.39MSEC XBRL filing
Total assets (annual): USD 68.49MSEC XBRL filing
Total liabilities (annual): USD 8.02MSEC XBRL filing
Shares outstanding (annual): 91.88MSEC XBRL filing
Current assets (annual): USD 68.35MSEC XBRL filing
Capex (annual): USD 33.95KSEC XBRL filing
Net income (annual): USD -36.12MSEC XBRL filing
Operating income (annual): USD -39.7MSEC XBRL filing
Cash & equivalents (annual): USD 66MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-01 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread